{"id":3700,"date":"2021-02-04T18:04:03","date_gmt":"2021-02-05T02:04:03","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3700"},"modified":"2021-02-04T18:04:03","modified_gmt":"2021-02-05T02:04:03","slug":"safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-coronavac-in-healthy-adults-aged-60-years-and-older-a-randomised-double-blind-placebo-controlled-phase-1-2-clinical","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/04\/safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-coronavac-in-healthy-adults-aged-60-years-and-older-a-randomised-double-blind-placebo-controlled-phase-1-2-clinical\/","title":{"rendered":"Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1\/2 Clinical Trial"},"content":{"rendered":"<p>In a randomized, double-blind, placebo-controlled phase 1\/2 trial of the inactivated SARS-CoV-2 vaccine CoronaVac conducted among healthy, seronegative adults aged \u226560 years (n=421), all adverse reactions were mild or moderate, with injection site pain as the most frequently reported reaction (9%). Seroconversion after two doses was reported in at least 90% of all dosage groups and none in the placebo groups.<\/p>\n<p><i>Wu et al. (Feb 3, 2021). Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1\/2 Clinical Trial. The Lancet Infectious Diseases. <\/i><a href=\"https:\/\/www.thelancet.com\/article\/S1473-3099(20)30843-4\/fulltext\">https:\/\/www.thelancet.com\/article\/S1473-3099(20)30843-4\/fulltext<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a randomized, double-blind, placebo-controlled phase 1\/2 trial of the inactivated SARS-CoV-2 vaccine CoronaVac conducted among healthy, seronegative adults aged \u226560 years (n=421), all adverse reactions were mild or moderate, with injection site pain as the most frequently reported reaction (9%). Seroconversion after two doses was reported in at least 90% of all dosage groups&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/04\/safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-coronavac-in-healthy-adults-aged-60-years-and-older-a-randomised-double-blind-placebo-controlled-phase-1-2-clinical\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-3700","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3700"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3700\/revisions"}],"predecessor-version":[{"id":3701,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3700\/revisions\/3701"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3700"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}